Citations

Clear

27 citation(s) found for "Spicka, I".

PF596 EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D‐VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK
Spencer, Andrew , Lentzsch, Suzanne , Spicka, I., Lauri, Birgitta, Lee, J.‐J., Nooka, A., Munder, Markus , Lee, C., Barreto, Wolney, Min, Chang‐Ki , Chanan‐Khan, A.A., Horvath, Noemi , Capra, Marcelo , Ovilla, Roberto, Jo, Jin-Hyeong, Shin, Ho‐Jin , Sonneveld, Pieter , Soong, David, Casneuf, Tineke, Ukropec, Jon, Qi, Ming , Mateos, M.‐V., Weisel, Katja C , Avet‐Loiseau, Hervé , Mark, Tomer M , Spicka, I., Masszi, Tamás , Levin, Mark-David , Bosi, Alberto , Hungria, Vânia , Cavo, Michèle , Quach, Hang , Corradini, Paolo , Beksaç, Meral , Chiu, C., Amin, H., Qi, M.

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 251

10.1097/01.hs9.0000560672.85259.7d Get It

Background:Patients (pts) with multiple myeloma associated with high cytogenetic risk abnormalities have poor outcomes. In CASTOR, D‐Vd prolonged progression‐free survival (PFS) vs bortezomib and dexamethasone (Vd) alone, and exhibited a manageable safety profile in pts with RRMM. We conducted a subgroup analysis of D‐Vd vs Vd in CASTOR, based on cytogenetic risk.Aims:The purpose of this analysis was to determine the efficacy and safety of D‐Vd in CASTOR based on cytogenetic risk status.Methods:Eligible pts received ≥1 prior line of therapy. Cytogenetic risk was based on a combined analysis of next‐generation sequencing (NGS) and fluorescence in situ hybridization (FISH)/karyotype testing. High‐risk pts had t(4;14), t(14;16), or del17p abnormalities. Standard (std)‐risk pts were confirmed negative for all 3 abnormalities. Minimal residual disease (MRD; 10–5) was assessed via NGS using clonoSEQ® assay V2.0.Results:In CASTOR (D‐Vd, n = 251; Vd, n = 247), high‐risk was confirmed in 26.7% and 25.9% of pts in the D‐Vd and Vd groups, respectively. At a median follow up of 40.0 months (mo), D‐Vd prolonged PFS vs Vd in pts with high‐ (median 13.4 vs 7.2 mo; HR, 0.40 [95% CI, 0.24–0.65]; P = 0.0002) or std‐risk (median 18.4 vs 6.8 mo; HR, 0.28 [95% CI, 0.20–0.37]; P <0.0001). Higher ORR was seen with D‐Vd vs Vd (high risk: 84.8% vs 60.0%; P = 0.0226; std risk: 85.4% vs 65.0%; P <0.0001), including deep responses of ≥CR (high risk: 33.3% vs 8.3%; std risk: 29.9% vs 10.2%) and ≥VGPR (high risk: 65.2% vs 35.0%; P = 0.0049; std risk: 64.3% vs 28.0%; P <0.0001). Higher rates of MRD negativity (high risk: 17.9% vs 0%; P = 0.0003; std risk: 13.3% vs 2.4%; P = 0.0003), and sustained MRD negativity for ≥6 mo (high risk: 16.4% vs 0%; P = 0.0006; std risk: 6.1% vs 1.8%; P = 0.0859) and ≥12 mo (high risk: 7.5% vs 0%; P = 0.0581; std risk: 1.8% vs 0%; P = 0.2477) were seen with D‐Vd vs Vd. D‐Vd significantly prolonged PFS vs Vd in pts with one prior line of therapy only (high risk: median 20.1 vs 8.4 mo; HR, 0.30 [95% CI, 0.14–0.64]; P = 0.0012; std risk: median 32.6 vs 7.9 mo; HR, 0.18 [95% CI, 0.11–0.29]; P <0.0001; Figure). Additionally, D‐Vd significantly prolonged PFS2 (high risk: median 27.9 vs 18.6 mo; HR, 0.59 [95% CI, 0.37–0.94]; P = 0.0258; std risk: median 40.1 vs 21.6 mo; HR, 0.43 [95% CI, 0.32–0.59]; P <0.0001) regardless of cytogenetic risk status.Additional data including safety analyses will be presented.Summary/Conclusion:Adding daratumumab to Vd demonstrates significant efficacy in pts with high‐risk RRMM including PFS2. Among high‐risk RRMM pts, MRD negativity was only achieved with D‐Vd. These findings support use of D‐Vd for high‐risk RRMM. NCT02136134image
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.
Palumbo, Antonio, Chanan‐Khan, Asher , Mateos, María‐Victoria , Qi, Ming , Schecter, Jordan M. , Amin, Himal, Qin, Xiang , Deraedt, William , Ahmadi, Tahamtan , Spencer, Andrew , Sonneveld, Pieter , Weisel, Katja C , Nooka, Ajay K. , Masszi, Tamás , Beksaç, Meral , Špıčka, Ivan , Hungria, Vânia , Mark, Tomer M , Qi, Ming

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: LBA4-LBA4

10.1200/jco.2016.34.15_suppl.lba4 Get It

Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.
Palumbo, Antonio , Chanan‐Khan, Asher , Mateos, María‐Victoria , Qi, Ming , Schecter, Jordan M. , Amin, Himal, Qin, Xiang , Deraedt, William , Ahmadi, Tahamtan , Spencer, Andrew , Sonneveld, Pieter , Weisel, Katja C , Nooka, Ajay K. , Masszi, Tamás , Beksaç, Meral , Špıčka, Ivan , Hungria, Vânia , Mark, Tomer M

Mayo Clinic

Journal of Clinical Oncology | May 11, 2017 | Volume: 34 | Issue: 18_suppl | Pages: LBA4-LBA4

10.1200/jco.2016.34.18_suppl.lba4 Get It

LBA4 Background: Daratumumab (D), a human anti-CD38 IgGκ mAb, induces deep and durable responses with a favorable safety profile in RRMM pts. We report a pre-specified interim analysis of the first randomized controlled study of D (CASTOR; NCT02136134). Methods: Pts with ≥1 prior line of therapy were randomized (1:1) to 8 cycles (q3w) of bortezomib (V)/dexamethasone (d) (V: 1.3 mg/m2sc on Days 1, 4, 8, 11; d: 20 mg po on Days 1, 2, 4, 5, 8, 9, 11, 12) ± D (16 mg/kg iv qw in Cycles 1-3, Day 1 of Cycles 4-8, then q4w until progression). Primary endpoint was PFS. Results: 498 pts (DVd, 251; Vd, 247) were randomized. Baseline demographics and disease characteristics were well balanced. Pts received a median of 2 prior lines of therapy (range 1-10). 66% received prior V; 76% received prior IMiD; 48% received prior PI and IMiD; 33% were IMiD-refractory; 32% were refractory to last line of prior therapy. With median follow-up of 7.4 months, D significantly improved median PFS (61% reduction in risk of progression) and TTP for DVd vs Vd (Table). D significantly increased ORR (83% vs 63%, P <0.0001), and doubled rates of ≥VGPR (59% vs 29%, P <0.0001), and ≥CR (19% vs 9%, P= 0.0012) for DVd vs Vd, respectively; median duration of response was NR vs 7.9 months, respectively. Most common (>25%) AEs (DVd/Vd) were thrombocytopenia (59%/44%), peripheral sensory neuropathy (47%/ 38%), diarrhea (32%/22%) and anemia (26%/31%). Most common grade 3/4 AEs (>10%) were thrombocytopenia (45%/33%), anemia (14%/16%), neutropenia (13%/4%). 7%/9% of pts discontinued due to a TEAE. D-associated infusion-related reactions (45% of pts) mostly occurred during the first infusion; most were grade 1/2 (grade 3/4, 9%/0%). Conclusions: D significantly improved PFS, TTP, and ORR in combination with Vd vs Vd alone. DVd doubled both VGPR and sCR/CR rates vs Vd alone. Safety of DVd is consistent with the known safety profile of D and Vd. The addition of D to Vd should be considered a new standard of care for RRMM pts currently receiving Vd alone. Clinical trial information: NCT02136134. [Table: see text]
IgM myeloma: A multicenter retrospective study of 134 patients
Castillo, Jorge J. , Brožová, Lucie , Czepiel, Jacek , Dávila, Julio , Ghobrial, Irene M. , Gozzetti, Alessandro , Gustine, Joshua , Hájek, Roman , Jayabalan, David , Laubach, Jacob P. , Lewicka, Barbara , Maisnar, Vladimír , Manasanch, Elisabet E. , Moreau, Philippe , Nahi, Hareth , Niesvizky, Rubén, Paba‐Prada, Claudia E., Pika, Tomáš, Pour, Luděk , Reagan, John L. , Richardson, Paul G. , Shah, Jatin J., Špıčka, Ivan , Vij, Ravi , Jurczyszyn, Artur , Crusoé, Edvan de Queiroz , Dispenzieri, Angela , Eveillard, Marion , Fiala, Mark A. , Hungria, Vânia , Jarkovský, Jiří , Morgan, Elizabeth A. , Richardson, Paul Gerard Guy , Waszczuk‐Gajda, Anna , Gertz, Morie A. , Hajek, Roman , Moreau, Philippe , Castillo, Jorge J , Ghobrial, Irene M , Gozzetti, Alessandro , Nahi, Hareth

Mayo Clinic

American Journal of Hematology | April 6, 2017 | Volume: 92 | Issue: 8 | Pages: 746-751

10.1002/ajh.24753 | PMID 28383205 Get It

AbstractIgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL−1 with 19% of patients presenting with levels >6,000 mg dL−1. International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma
Stewart, A. Keith, Dimopoulos, Meletios Α. , Masszi, Tamás , Špıčka, Ivan , Oriol, Albert , Hájek, Roman , Rosiñol, Laura , Niesvizky, Rubén, Miguel, Jesús F. San , Buchanan, Jacqui, Cocks, Kim , Yang, Xinqun, Xing, Biao, Zojwalla, Naseem J., Tonda, Margaret, Moreau, Philippe , Palumbo, Antonio , Dimopoulos, Meletios A, Siegel, David S. , San-Miguel, Jesus F, Ludwig, Heinz , Zojwalla, Naseem, Jakubowiak, Andrzej , Hajek, Roman , Dimopoulos, Meletios A , Moreau, Philippe , San-Miguel, Jesus , Masszi, Tamas , Oriol, Albert

Mayo Clinic

Journal of Clinical Oncology | September 7, 2016 | Volume: 34 | Issue: 32 | Pages: 3921-3930

10.1200/jco.2016.66.9648 | PMID 27601539 Get It

Purpose To determine the effects of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) on health-related quality of life (HR-QoL) in the Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone for the Treatment of Patients With Relapsed Multiple Myeloma (ASPIRE) trial. Methods Patients with relapsed multiple myeloma were randomly assigned to receive KRd or Rd. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and myeloma-specific module were administered at baseline; day 1 of cycles 3, 6, 12, and 18; and after treatment. The Global Health Status/Quality of Life (GHS/QoL) scale and seven subscales (fatigue, nausea and vomiting, pain, physical functioning, role functioning, disease symptoms, and adverse effects of treatment) were compared between groups using a mixed model for repeated measures. The percentages of responders with ≥ 5- or 15-point GHS/QoL improvement at each cycle were compared between groups. Results Baseline questionnaire compliance was excellent (94.1% of randomly assigned patients). KRd patients had higher GHS/QoL scores versus Rd patients over 18 treatment cycles (two-sided P < .001). The minimal important difference was met at cycle 12 (5.6 points) and approached at cycle 18 (4.8 points). There was no difference between groups for the other prespecified subscales from ASPIRE. A higher proportion of KRd patients met the GHS/QoL responder definition (≥ 5-point improvement) with statistical differences at cycle 12 (KRd v Rd patients, 25.5% v 17.4%, respectively) and 18 (KRd v Rd patients, 24.2% v 12.9%, respectively). Conclusion KRd improves GHS/QoL without negatively affecting patient-reported symptoms when compared with Rd. These data further support the benefit of KRd in patients with relapsed multiple myeloma.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Avet‐Loiseau, Hervé , Dimopoulos, Meletios Α. , Špıčka, Ivan , Masszi, Tamás , Hájek, Roman , Rosiñol, Laura , Mihaylov, Georgi , Maisnar, Vladimír , Mateos, María‐Victoria , Wang, Michael , Niesvizky, Rubén, Oriol, Albert , Minařík, Jiří , Palumbo, Antonio , Bensinger, William, Kukreti, Vishal , Ben‐Yehuda, Dina, Stewart, A. Keith, Obreja, Mihaela, Moreau, Philippe , Nahi, Hareth , Goranova‐Marinova, Veselina , Fonseca, Rafaël , Siegel, David S. , Goranova-Marinova, Vesselina S , Jakubowiak, Andrzej , Hajek, Roman , Dimopoulos, Meletios A , Moreau, Philippe , Masszi, Tamas , Nahi, Hareth , Oriol, Albert

Mayo Clinic

Blood | July 21, 2016 | Volume: 128 | Issue: 9 | Pages: 1174-1180

10.1182/blood-2016-03-707596 | PMID 27439911 Get It

Key Points KRd has a favorable benefit-risk profile compared with Rd, regardless of baseline cytogenetic risk status, in patients with relapsed MM. KRd improves but does not abrogate the poor prognosis associated with high-risk cytogenetics in patients with relapsed MM.